The Blue Oak founders were previously key drivers in the discovery of a new class of antipsychotic drugs that have recently achieved breakthrough status at the FDA. By combining Blue Oak’s therapeutic area expertise with Exscientia’s unique proven AI technologies, we are rapidly developing best-in-class 3rd generation antipsychotics.
EEG brain-mapping studies in rodents, primates and man will provide a PD biomarker to establish effective clinical doses. phMRI brain imaging in man is planned to confirm appropriate modulation of the dopamine and serotonergic circuits needed for therapeutic efficacy.
We anticipate submitting an investigational new drug (IND) application with the U.S. FDA in 2023.
Blue Oak research demonstrates that OAK-0011799 also has potential for the treatment of positive and negative symptoms in schizophrenia.